company background image
AGIO logo

Agios Pharmaceuticals NasdaqGS:AGIO Stock Report

Last Price

US$54.41

Market Cap

US$3.1b

7D

-7.2%

1Y

147.8%

Updated

20 Nov, 2024

Data

Company Financials +

Agios Pharmaceuticals, Inc.

NasdaqGS:AGIO Stock Report

Market Cap: US$3.1b

Agios Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Agios Pharmaceuticals
Historical stock prices
Current Share PriceUS$54.41
52 Week HighUS$62.58
52 Week LowUS$20.96
Beta0.75
11 Month Change19.16%
3 Month Change19.06%
1 Year Change147.77%
33 Year Change46.07%
5 Year Change39.30%
Change since IPO73.95%

Recent News & Updates

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Recent updates

We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Sep 26
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Aug 27

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 04
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Jun 12

Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Jun 02
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth

Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Feb 17
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Jan 16
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Nov 09
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%

Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Sep 26
Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 08
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Feb 06
We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely

Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Oct 18
Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans

Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU

Sep 16

Agios adds more than 13% after Novo deal to acquire rival Forma

Sep 01

Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07

Aug 04

Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp

Jul 26

Agios Pharmaceuticals appoints new board chair, CEO

Jul 12

Agios: Approved Product, Upcoming Catalysts

May 10

Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

May 10
Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?

Agios Pharmaceuticals With FDA Approval Is A Buy

Feb 23

Agios Before The February PDUFA

Jan 20

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Dec 21
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%

Shareholder Returns

AGIOUS BiotechsUS Market
7D-7.2%-7.5%-1.2%
1Y147.8%14.1%30.4%

Return vs Industry: AGIO exceeded the US Biotechs industry which returned 14.1% over the past year.

Return vs Market: AGIO exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is AGIO's price volatile compared to industry and market?
AGIO volatility
AGIO Average Weekly Movement6.8%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: AGIO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AGIO's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007385Brian Goffwww.agios.com

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.

Agios Pharmaceuticals, Inc. Fundamentals Summary

How do Agios Pharmaceuticals's earnings and revenue compare to its market cap?
AGIO fundamental statistics
Market capUS$3.10b
Earnings (TTM)US$674.31m
Revenue (TTM)US$32.87m

4.6x

P/E Ratio

94.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AGIO income statement (TTM)
RevenueUS$32.87m
Cost of RevenueUS$299.46m
Gross Profit-US$266.58m
Other Expenses-US$940.89m
EarningsUS$674.31m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.82
Gross Margin-811.00%
Net Profit Margin2,051.38%
Debt/Equity Ratio0%

How did AGIO perform over the long term?

See historical performance and comparison